We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+7.59%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$222M
AUM Growth
-$48.8M
Cap. Flow
-$57.8M
Cap. Flow %
-26.1%
Top 10 Hldgs %
90.89%
Holding
28
New
6
Increased
2
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$25.2M
2
BLUE
bluebird bio
BLUE
+$10.2M
3
LENS
Presbia PLC Ordinary Shares
LENS
+$2.57M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.52M
5
FBIO icon
Fortress Biotech
FBIO
+$1.39M

Top Sells

Rank Stock Value
1
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$39.9M
2
RLYP
RELYPSA INC COM
RLYP
+$15.1M
3
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$13.9M
4
DYAX
DYAX CORPORATION
DYAX
+$8.51M
5
XNPT
XENOPORT, INC.
XNPT
+$7.39M

Sector Composition

Rank Sector Weight
1 Healthcare 65.59%
2 Consumer Discretionary 0.01%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$36.3B
$37.1M 16.75%
355,395
+15,000
+4% +$1.52M
DYAX
2
DELISTED
DYAX CORPORATION
DYAX
$26.6M 11.99%
1,585,098
-546,710
-26% -$8.51M
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$23.8M 10.75%
990,981
-125,000
-11% -$2.81M
KITE
4
DELISTED
Kite Pharma, Inc.
KITE
$21.7M 9.78%
+375,623
New +$25.2M
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$2.37B
$20.4M 9.22%
2,261,361
– –
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
$19.5M 8.79%
1,064,247
– –
ARWR icon
7
Arrowhead Research
ARWR
$12.1B
$16.3M 7.36%
2,410,000
-200,000
-8% -$1.42M
ACHN
8
DELISTED
Achillion Pharmaceuticals
ACHN
$16M 7.22%
1,622,633
– –
BLUE
9
DELISTED
bluebird bio
BLUE
$12.1M 5.45%
+7,720
New +$10.2M
GYRE icon
10
Gyre Therapeutics
GYRE
$662M
$7.92M 3.57%
3,385
– –
ZSPH
11
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$3M 1.35%
71,315
-303,506
-81% -$13.9M
ASMB icon
12
Assembly Biosciences
ASMB
$506M
$2.7M 1.22%
17,000
– –
LENS
13
DELISTED
Presbia PLC Ordinary Shares
LENS
$2.59M 1.17%
+350,000
New +$2.57M
ADVM
14
DELISTED
Adverum Biotechnologies
ADVM
$2.08M 0.94%
5,130
+130
+3% +$55K
RPRX
15
DELISTED
Repros Therapeutics Inc.
RPRX
$1.97M 0.89%
229,364
– –
FBIO icon
16
Fortress Biotech
FBIO
$111M
$1.93M 0.87%
+33,333
New +$1.39M
CYTR
17
DELISTED
CytRx Corp
CYTR
$1.9M 0.86%
93,969
-23,531
-20% -$438K
LPCN icon
18
Lipocine
LPCN
$17.1M
$1.44M 0.65%
12,314
– –
TARO
19
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$1.23M 0.56%
8,721
-259,162
-97% -$39.9M
RLYP
20
DELISTED
RELYPSA INC COM
RLYP
$1.15M 0.52%
31,872
-418,367
-93% -$15.1M
APEN
21
DELISTED
Apollo Endosurgery, Inc.
APEN
$148K 0.07%
779
– –
SHAK icon
22
Shake Shack
SHAK
$2.3B
$25K 0.01%
+500
New +$22.4K
TENX icon
23
Tenax Therapeutics
TENX
$385M
– –
0
– –
BRK.B icon
24
Berkshire Hathaway Class B
BRK.B
$1.07T
$7K ﹤0.01%
+50
New +$7.36K
PLX icon
25
Protalix BioTherapeutics
PLX
$191M
– –
-84,385
Closed -$1.55M
1
2

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q1 2015 Portfolio in Review

As of Q1 2015, RTW Investments held 28 positions worth $222M, down 18% from $270M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

RTW Investments withdrew a net $57.8M in Q1 2015, closing 4 positions and reducing 7 holdings. Its most notable exit was XENOPORT, INC., an estimated $7.39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 68% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, RTW Investments opened a new position in Kite Pharma, Inc. worth $21.7M.

  • RTW Investments's largest Q1 2015 buy was Kite Pharma, Inc.: 375,623 shares worth $21.7M.
  • RTW Investments added most to Alnylam Pharmaceuticals in Q1 2015, an estimated $1.52M increase.
  • RTW Investments's biggest Q1 2015 reduction was Taro Pharmaceutical Industries Ltd., cutting an estimated $39.9M.
  • RTW Investments fully exited XENOPORT, INC. in Q1 2015, selling an estimated $7.39M.
  • RTW Investments's ten largest holdings make up 91% of its $222M portfolio in Q1 2015.
  • RTW Investments opened 6 new positions and closed 4 in Q1 2015.
  • RTW Investments's portfolio value fell 18% quarter-over-quarter to $222M.

Based on RTW Investments's 13F filing for Q1 2015, filed 21 May 2015.